United States:
Podcast: What's New In Washington: What Congress Is Doing About Drug Pricing And Surprise Medical Billing
27 November 2019
Akin Gump Strauss Hauer & Feld LLP
To print this article, all you need is to be registered or login on Mondaq.com.
In this episode, Akin Gump health care and life sciences senior
counsel
Taylor Jones and public law and policy senior policy advisor
Julie Nolan discuss draft legislation currently on Capitol Hill
focusing on drug pricing and surprise medical billing.
Among the topics covered:
- What's driving legislation?
- Which draft bills have the most
support?
- What role does the international
pharmaceutical market play?
- What impact will impeachment
proceedings have?
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
Healthcare Policy Developments To Watch In 2024
Crowell & Moring LLP
The ever-changing healthcare policy landscape will witness at the federal level regulatory changes driven by the need to transform healthcare delivery, quality and innovation.
The FDA And The Future Of AI Oversight
Manatt, Phelps & Phillips LLP
In January 2024, the U.S. Government Accountability Office (GAO) issued a report highlighting current obstacles to the U.S. Food and Drug Administration's (FDA) timely and effective regulation...